Study patient characteristics
| . | All patients (n = 423) . | BCP-ALL patients (n = 260) . | T-ALL patients (n = 163) . |
|---|---|---|---|
| Patient-related characteristics | |||
| Trial, 2003/2005 | 103/320 | 66/194 | 37/126 |
| Median age, years (range) | 31.2 (15.2-59.9) | 34.5 (15.2-59.9) | 29.6 (16.3-57.0) |
| Gender, M/F | 264/159 | 147/113 | 117/46 |
| Disease-related characteristics | |||
| Median WBC, 109/L (range) | 15.4 (0.4-456) | 9.3 (0.4-396) | 32.1 (1.4-456) |
| CNS involvement,* Y/N/unknown | 33/386/4 | 15/242/3 | 18/144/1 |
| Complex karyotype,* Y/N/failure/unknown | 32/322/65/4 | 18/200/40/2 | 14/122/25/2 |
| Low hypodiploidy/near triploidy,* Y/N/unknown | 11/363/49 | 11/219/30 | 0/144/19 |
| WBC ≥30 × 109/L (BCP-ALL),* Y/N | — | 67/193 | — |
| CD10-negative immature ALL,* Y/N/unknown | — | 67/183/10 | — |
| MLL gene rearrangement (t[4;11] or other),* Y/N/unknown | — | 29/224/7 | — |
| t(1;19),* Y/N/unknown | — | 14/230/16 | — |
| IKZF1 gene deletion, Y/N/unknown | — | 54/162/44 | — |
| WBC ≥100 × 109/L (T-ALL), Y/N | — | — | 37/126 |
| Pro-T/mature-T ALL,† Y/N/unknown | — | — | 22/129/12 |
| TLX1 overexpression, Y/N/unknown | — | — | 29/98/36 |
| NOTCH1/FBXW7 gene mutation, Y/N/unknown | — | — | 90/46/27 |
| High-risk NOTCH1/FBXW7/RAS/PTEN genetics, Y/N/unknown | — | — | 60/65/38 |
| Response-related characteristics | |||
| Resistance to steroid prephase,* Y/N/unknown | 102/320/1 | 42/218/0 | 60/102/1 |
| Poor early BM blast clearance,* Y/N/unknown | 169/245/9 | 107/146/7 | 62/99/2 |
| MRD1 level ≥10−4, Y/N (%) | 158/265 (37.4%) | 111/149 (42.7%) | 47/116 (28.8%) |
| . | All patients (n = 423) . | BCP-ALL patients (n = 260) . | T-ALL patients (n = 163) . |
|---|---|---|---|
| Patient-related characteristics | |||
| Trial, 2003/2005 | 103/320 | 66/194 | 37/126 |
| Median age, years (range) | 31.2 (15.2-59.9) | 34.5 (15.2-59.9) | 29.6 (16.3-57.0) |
| Gender, M/F | 264/159 | 147/113 | 117/46 |
| Disease-related characteristics | |||
| Median WBC, 109/L (range) | 15.4 (0.4-456) | 9.3 (0.4-396) | 32.1 (1.4-456) |
| CNS involvement,* Y/N/unknown | 33/386/4 | 15/242/3 | 18/144/1 |
| Complex karyotype,* Y/N/failure/unknown | 32/322/65/4 | 18/200/40/2 | 14/122/25/2 |
| Low hypodiploidy/near triploidy,* Y/N/unknown | 11/363/49 | 11/219/30 | 0/144/19 |
| WBC ≥30 × 109/L (BCP-ALL),* Y/N | — | 67/193 | — |
| CD10-negative immature ALL,* Y/N/unknown | — | 67/183/10 | — |
| MLL gene rearrangement (t[4;11] or other),* Y/N/unknown | — | 29/224/7 | — |
| t(1;19),* Y/N/unknown | — | 14/230/16 | — |
| IKZF1 gene deletion, Y/N/unknown | — | 54/162/44 | — |
| WBC ≥100 × 109/L (T-ALL), Y/N | — | — | 37/126 |
| Pro-T/mature-T ALL,† Y/N/unknown | — | — | 22/129/12 |
| TLX1 overexpression, Y/N/unknown | — | — | 29/98/36 |
| NOTCH1/FBXW7 gene mutation, Y/N/unknown | — | — | 90/46/27 |
| High-risk NOTCH1/FBXW7/RAS/PTEN genetics, Y/N/unknown | — | — | 60/65/38 |
| Response-related characteristics | |||
| Resistance to steroid prephase,* Y/N/unknown | 102/320/1 | 42/218/0 | 60/102/1 |
| Poor early BM blast clearance,* Y/N/unknown | 169/245/9 | 107/146/7 | 62/99/2 |
| MRD1 level ≥10−4, Y/N (%) | 158/265 (37.4%) | 111/149 (42.7%) | 47/116 (28.8%) |